The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway

L.M. t Hart; A. Fritsche; G. Nijpels; N. van Leeuwen; L.A. Donnelly; J.M. Dekker; M. Alssema; J. Fadista; F. Carlotti; A.P. Gjesing; C.N. Palmer; T.W. van Haeften; S.A. Herzberg-Schafer; A.M. Simonis-Bik; J.J. Houwing-Duistermaat; Q. Helmer; J. Deelen; B. Guigas; T. Hansen; F. Machicao; G. Willemsen; R.J. Heine; M.H. Kramer; J.J. Holst; E.J. de Koning; H.U. Haring; O. Pedersen; L. Groop; E.J. de Geus; P.E. Slagboom; D.I. Boomsma; E.M. Eekhoff; E.R. Pearson; M. Diamant

doi:10.2337/db13-0227

The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway

L.M. t Hart, A. Fritsche, G. Nijpels, N. van Leeuwen, L.A. Donnelly, J.M. Dekker, M. Alssema, J. Fadista, F. Carlotti, A.P. Gjesing, C.N. Palmer, T.W. van Haeften, S.A. Herzberg-Schafer, A.M. Simonis-Bik, J.J. Houwing-Duistermaat, Q. Helmer, J. Deelen, B. Guigas, T. Hansen, F. MachicaoG. Willemsen, R.J. Heine, M.H. Kramer, J.J. Holst, E.J. de Koning, H.U. Haring, O. Pedersen, L. Groop, E.J. de Geus, P.E. Slagboom, D.I. Boomsma, E.M. Eekhoff, E.R. Pearson, M. Diamant

Hubrecht Institute

Research output: Contribution to journal/periodical › Article › Scientific › peer-review

84 Citations (Scopus)

Abstract

The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeostasis and enhances beta-cell function. GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. Using the Metabochip, we identified three novel genetic loci with large effects (30-40%) on GLP-1-stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individuals (TMEM114; CHST3 and CTRB1/2; n = 232; all P

Original language	English
Pages (from-to)	3275-3281
Journal	Diabetes
Volume	62
Issue number	9
DOIs	https://doi.org/10.2337/db13-0227
Publication status	Published - 2013

Access to Document

10.2337/db13-0227

Cite this

t Hart, L. M., Fritsche, A., Nijpels, G., van Leeuwen, N., Donnelly, L. A., Dekker, J. M., Alssema, M., Fadista, J., Carlotti, F., Gjesing, A. P., Palmer, C. N., van Haeften, T. W., Herzberg-Schafer, S. A., Simonis-Bik, A. M., Houwing-Duistermaat, J. J., Helmer, Q., Deelen, J., Guigas, B., Hansen, T., ... Diamant, M. (2013). The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes, 62(9), 3275-3281. https://doi.org/10.2337/db13-0227

@article{a518746466494d97ad7dee3be1d4775c,

title = "The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway",

abstract = "The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeostasis and enhances beta-cell function. GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. Using the Metabochip, we identified three novel genetic loci with large effects (30-40%) on GLP-1-stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individuals (TMEM114; CHST3 and CTRB1/2; n = 232; all P",

author = "{t Hart}, L.M. and A. Fritsche and G. Nijpels and {van Leeuwen}, N. and L.A. Donnelly and J.M. Dekker and M. Alssema and J. Fadista and F. Carlotti and A.P. Gjesing and C.N. Palmer and {van Haeften}, T.W. and S.A. Herzberg-Schafer and A.M. Simonis-Bik and J.J. Houwing-Duistermaat and Q. Helmer and J. Deelen and B. Guigas and T. Hansen and F. Machicao and G. Willemsen and R.J. Heine and M.H. Kramer and J.J. Holst and {de Koning}, E.J. and H.U. Haring and O. Pedersen and L. Groop and {de Geus}, E.J. and P.E. Slagboom and D.I. Boomsma and E.M. Eekhoff and E.R. Pearson and M. Diamant",

note = "Reporting year: 2013",

year = "2013",

doi = "10.2337/db13-0227",

language = "English",

volume = "62",

pages = "3275--3281",

journal = "Diabetes",

issn = "0012-1797",

publisher = "American Diabetes Association Inc.",

number = "9",

}

t Hart, LM, Fritsche, A, Nijpels, G, van Leeuwen, N, Donnelly, LA, Dekker, JM, Alssema, M, Fadista, J, Carlotti, F, Gjesing, AP, Palmer, CN, van Haeften, TW, Herzberg-Schafer, SA, Simonis-Bik, AM, Houwing-Duistermaat, JJ, Helmer, Q, Deelen, J, Guigas, B, Hansen, T, Machicao, F, Willemsen, G, Heine, RJ, Kramer, MH, Holst, JJ, de Koning, EJ, Haring, HU, Pedersen, O, Groop, L, de Geus, EJ, Slagboom, PE, Boomsma, DI, Eekhoff, EM, Pearson, ER & Diamant, M 2013, 'The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway', Diabetes, vol. 62, no. 9, pp. 3275-3281. https://doi.org/10.2337/db13-0227

TY - JOUR

T1 - The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway

AU - t Hart, L.M.

AU - Fritsche, A.

AU - Nijpels, G.

AU - van Leeuwen, N.

AU - Donnelly, L.A.

AU - Dekker, J.M.

AU - Alssema, M.

AU - Fadista, J.

AU - Carlotti, F.

AU - Gjesing, A.P.

AU - Palmer, C.N.

AU - van Haeften, T.W.

AU - Herzberg-Schafer, S.A.

AU - Simonis-Bik, A.M.

AU - Houwing-Duistermaat, J.J.

AU - Helmer, Q.

AU - Deelen, J.

AU - Guigas, B.

AU - Hansen, T.

AU - Machicao, F.

AU - Willemsen, G.

AU - Heine, R.J.

AU - Kramer, M.H.

AU - Holst, J.J.

AU - de Koning, E.J.

AU - Haring, H.U.

AU - Pedersen, O.

AU - Groop, L.

AU - de Geus, E.J.

AU - Slagboom, P.E.

AU - Boomsma, D.I.

AU - Eekhoff, E.M.

AU - Pearson, E.R.

AU - Diamant, M.

N1 - Reporting year: 2013

PY - 2013

Y1 - 2013

N2 - The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeostasis and enhances beta-cell function. GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. Using the Metabochip, we identified three novel genetic loci with large effects (30-40%) on GLP-1-stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individuals (TMEM114; CHST3 and CTRB1/2; n = 232; all P

AB - The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeostasis and enhances beta-cell function. GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. Using the Metabochip, we identified three novel genetic loci with large effects (30-40%) on GLP-1-stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individuals (TMEM114; CHST3 and CTRB1/2; n = 232; all P

U2 - 10.2337/db13-0227

DO - 10.2337/db13-0227

M3 - Article

SN - 0012-1797

VL - 62

SP - 3275

EP - 3281

JO - Diabetes

JF - Diabetes

IS - 9

ER -

The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway

Abstract

Access to Document

Fingerprint

Cite this